**List of Progress in Hematology "Review Series" 2020-2021**

*****2021*****

**Advances in diagnosis and treatment of disseminated intravascular coagulation (Edited by Hidesaku Asakura)**

1. Asakura H. Diversity of disseminated intravascular coagulation and selection of appropriate treatments. Int J Hematol. 2021;113:10-4.
   https://link.springer.com/article/10.1007/s12185-020-03030-5

2. Yamada S, Asakura H. Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations. Int J Hematol. 2021;113:15-23.
   https://link.springer.com/article/10.1007/s12185-020-03028-z

3. Iba T, Connors JM, Nagaoka I, Levy JH. Recent advances in the research and management of sepsis-associated DIC. Int J Hematol. 2021;113:24-33
   https://link.springer.com/article/10.1007/s12185-020-03053-y

4. Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021;113:34-44.
   https://link.springer.com/article/10.1007/s12185-020-02992-w

5. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2021;113:45-57.
   https://link.springer.com/article/10.1007/s12185-020-03029-y

**Aiming for the final goal (Edited by Shinya Kimura)**


1. Kimura S. Evolution of CML treatment. Int J Hematol. 2021; 113:622-3.
https://link.springer.com/article/10.1007/s12185-021-03128-4

2. Morita K, Sasaki K. Current status and novel strategy of CML. Int J Hematol. 2021; 113:624-31.
https://link.springer.com/article/10.1007/s12185-021-03127-5

3. Lee H, Basso IN, Kim DDH. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol. 2021; 113:632-41.
https://link.springer.com/article/10.1007/s12185-021-03126-6

4. Ureshino H. Treatment-free remission and immunity in chronic myeloid leukemia. Int J Hematol. 2021; 113:642-7.
https://link.springer.com/article/10.1007/s12185-021-03117-7

5. Naka K. New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism. Int J Hematol. 2021; 113:648-55.
https://link.springer.com/article/10.1007/s12185-021-03112-y


**CAR-T cell therapy, Now the time for the next！(Edited by Hiroshi Fujiwara)**


1. Fujiwara H. Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells. Int J Hematol. 2021;114:529-31.
https://link.springer.com/article/10.1007/s12185-021-03213-8

2. Lundh S, Maji S, Melenhorst JJ. Next-generation CAR T cells to overcome current drawbacks. Int J Hematol. 2021; 114:532-43. https://link.springer.com/article/10.1007/s12185-020-02923-9

3. Wang X, Diamond DJ, Forman SJ, Nakamura R. Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. Int J Hematol. 2021; 114:544-53. https://link.springer.com/article/10.1007/s12185-021-03215-6

4. Biederstädt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. 2021; 114:554-71. https://link.springer.com/article/10.1007/s12185-021-03209-4

5. Ueda T, Kaneko S. International Journal of Hemat Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors. Int J Hematol. 2021; 114:572-9. https://link.springer.com/article/10.1007/s12185-020-02951-5

*****2020*****

**Current progress and future direction in the treatment for haemophilia (Edited by Midori Shima)**

**1.** Kitazawa T, Shima M. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity. Int J Hematol. 2020; 111:20–30. https://link.springer.com/article/10.1007/s12185-018-2545-9

**2.** Ohmori T. Advances in gene therapy for hemophilia: basis, current status, and future perspectives. Int J Hematol. 2020; 111:31–41. https://link.springer.com/article/10.1007/s12185-018-2545-9

**3.** Chowdary P. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. Int J Hematol.

2020; 111:42–50.
https://link.springer.com/article/10.1007/s12185-018-2548-6

**Progress in elucidation of molecular pathophysiology and its application to therapeutic decisions of MPNs (Edited by Katsuto Takenaka)**

**1.** Jia R, Kralovics R. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions. Int J Hematol. 2020; 111:182–91.
https://link.springer.com/article/10.1007/s12185-019-02778-9

**2.** Bose P, Verstovsek S. Mutational profiling in myelofibrosis: implications for management. Int J Hematol. 2020; 111:192–9.
https://link.springer.com/article/10.1007/s12185-019-02758-z

**3.** Araki M, Komatsu N. The role of calreticulin mutations in myeloproliferative neoplasms. Int J Hematol. 2020; 111:200-5.
https://link.springer.com/article/10.1007/s12185-019-02800-0

**4.** Shide K. The role of driver mutations in myeloproliferative neoplasms: insights from mouse models. Int J Hematol. 2020; 111:206-16.
https://link.springer.com/article/10.1007/s12185-019-02803-x

**Recent Advances in Biology and Treatment of Multiple Myeloma (Edited by Hirokazu Tanaka)**

1. Kikuchi J. Molecular basis of clonal evolution in multiple myeloma. Int J Hematol. 2020; 111:496–511.
https://link.springer.com/article/10.1007/s12185-020-02829-6

2. Suzuki K. Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost. Int J Hematol. 2020; 111:512-8.
https://link.springer.com/article/10.1007/s12185-020-02841-w

3. Takamatsu H. Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan. Int J Hematol. 2020; 111:519-29.
https://link.springer.com/article/10.1007/s12185-020-02828-7
4. Hosen N. Chimeric antigen receptor T-cell therapy for multiple myeloma. Int J Hematol. 2020; 111:530-4.
https://link.springer.com/article/10.1007/s12185-020-02827-8

**B1cells: their ontogeny and malignant counterpart (Edited by Naoyuki Katayama)**

1. Yoshimoto M. The ontogeny of murine B-1a cells. Int J Hematol. 2020; 111:622-7.
https://link.springer.com/article/10.1007/s12185-019-02787-8
2. Kageyama Y, Katayama N. Ontogeny of human B1 cells. Int J Hematol. 2020; 111:628-33.
https://link.springer.com/article/10.1007/s12185-019-02775-y
3. Kikushige Y. Pathophysiology of chronic lymphocytic leukemia and human B1 cell development. Int J Hematol. 2020; 111:634-41.
https://link.springer.com/article/10.1007/s12185-019-02788-7
4. Suzumiya J, Takizawa J. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal? Int J Hematol. 2020; 111:642-56.
https://link.springer.com/article/10.1007/s12185-020-02867-0